The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The grant is designated for the research and development of Pyronaridine
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Majority of organizations are looking to increase investments in public and hybrid cloud
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
